Boston, MA -- (SBWIRE) -- 08/20/2012 -- This analysis evaluates the company's strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the company's historical and forecast financial performance. The report also gives an in-depth analysis of the company's key prescription pharmaceutical product, and provides a forecast sales performance for this drug.

Scope

- Detailed analysis of the financial benefits and risks related to the adoption of Omontys at dialysis centers
- Discussion of the company's strategy, commercial relationships, and forthcoming catalysts
- Sales forecasts through to 2017
- Financial analysis of the company, including operating performance forecasts through to 2017

View Full Report Details and Table of Contents

Highlights

This report contains patient-based forecasts for Affymax's Omontys, a once monthly erythropoiesis-stimulating agent (ESA) which was recently approved in the US for the treatment of anemia in dialysis patients with chronic kidney disease. Omontys is the first ESA to challenge Amgen's US monopoly of Epogen and Aranesp in the dialysis setting.

Reasons to Get this Report

- Analyze how the performance of Omontys will shape Affymax's growth prospects
- Assess the current ESA market in the dialysis setting and how various factors are forecast to affect Omontys sales
- See how Affymax's development and marketing relationship with Takeda will contribute to the company's overall strategic outlook

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- MAP Pharmaceuticals: PharmaVitae Report
- Ariad Pharmaceuticals: PharmaVitae Report
- Regeneron Pharmaceuticals, Inc.: PharmaVitae Report
- Acorda Therapeutics: PharmaVitae Report
- Amylin Pharmaceuticals, Inc.: PharmaVitae Report
- Incyte Corporation: PharmaVitae Report
- Amarin Corporation plc: PharmaVitae Report
- United Therapeutics Corporation: PharmaVitae Report
- Dendreon Corporation: PharmaVitae Report
- Merck & Co., Inc.: PharmaVitae Report